JP7329244B2 - Ｈｐｖ１６陽性癌の治療コントロールのための血清検査 - Google Patents

Ｈｐｖ１６陽性癌の治療コントロールのための血清検査 Download PDF

Info

Publication number
JP7329244B2
JP7329244B2 JP2019532928A JP2019532928A JP7329244B2 JP 7329244 B2 JP7329244 B2 JP 7329244B2 JP 2019532928 A JP2019532928 A JP 2019532928A JP 2019532928 A JP2019532928 A JP 2019532928A JP 7329244 B2 JP7329244 B2 JP 7329244B2
Authority
JP
Japan
Prior art keywords
hpv16
antibody
antigen
capsid
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019532928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020501162A5 (https=
JP2020501162A (ja
Inventor
ラルフ ヒルフリッヒ
Original Assignee
アプヴィリス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプヴィリス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical アプヴィリス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2020501162A publication Critical patent/JP2020501162A/ja
Publication of JP2020501162A5 publication Critical patent/JP2020501162A5/ja
Priority to JP2022200001A priority Critical patent/JP2023029377A/ja
Application granted granted Critical
Publication of JP7329244B2 publication Critical patent/JP7329244B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019532928A 2016-12-13 2017-12-13 Ｈｐｖ１６陽性癌の治療コントロールのための血清検査 Active JP7329244B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022200001A JP2023029377A (ja) 2016-12-13 2022-12-15 Ｈｐｖ１６陽性癌の治療コントロールのための血清検査

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102016124171.7A DE102016124171A1 (de) 2016-12-13 2016-12-13 Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen
DE102016124171.7 2016-12-13
PCT/EP2017/082506 WO2018108957A1 (en) 2016-12-13 2017-12-13 Serologic test for therapy control of hpv16 positive carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022200001A Division JP2023029377A (ja) 2016-12-13 2022-12-15 Ｈｐｖ１６陽性癌の治療コントロールのための血清検査

Publications (3)

Publication Number Publication Date
JP2020501162A JP2020501162A (ja) 2020-01-16
JP2020501162A5 JP2020501162A5 (https=) 2021-02-04
JP7329244B2 true JP7329244B2 (ja) 2023-08-18

Family

ID=61027644

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019532928A Active JP7329244B2 (ja) 2016-12-13 2017-12-13 Ｈｐｖ１６陽性癌の治療コントロールのための血清検査
JP2022200001A Pending JP2023029377A (ja) 2016-12-13 2022-12-15 Ｈｐｖ１６陽性癌の治療コントロールのための血清検査

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022200001A Pending JP2023029377A (ja) 2016-12-13 2022-12-15 Ｈｐｖ１６陽性癌の治療コントロールのための血清検査

Country Status (22)

Country Link
US (2) US10852303B2 (https=)
EP (1) EP3384292B1 (https=)
JP (2) JP7329244B2 (https=)
KR (1) KR102433541B1 (https=)
CN (1) CN110073219B (https=)
BR (1) BR112019011681A2 (https=)
CA (1) CA3045729A1 (https=)
CY (1) CY1124297T1 (https=)
DE (1) DE102016124171A1 (https=)
DK (1) DK3384292T3 (https=)
ES (1) ES2880489T3 (https=)
HR (1) HRP20211080T1 (https=)
HU (1) HUE054969T2 (https=)
LT (1) LT3384292T (https=)
PL (1) PL3384292T3 (https=)
PT (1) PT3384292T (https=)
RS (1) RS62135B1 (https=)
RU (1) RU2757629C2 (https=)
SI (1) SI3384292T1 (https=)
SM (1) SMT202100421T1 (https=)
WO (1) WO2018108957A1 (https=)
ZA (1) ZA201804516B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102022127779A1 (de) 2022-10-20 2024-04-25 Ralf Hilfrich Serologischer Test zum Nachweis von Antikörpern gegen HPV und Testkit

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524076A (ja) 2002-04-30 2005-08-11 メルク　エンド　カムパニー　インコーポレーテッド ヒトパピローマウイルス多重アッセイ
US20130244228A1 (en) 2010-12-03 2013-09-19 Ralf Hilfrich Rapid test for the qualitative and/or quantitative analysis of antibodies against human papilloma viruses (hpv) present in body fluid, and device for carrying out the rapid test
US20140356861A1 (en) 2011-09-19 2014-12-04 Ralf Hilfrich Method for checking the self-healing process carried out by the immune system of a test subject infected with human papilloma virus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) * 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US20020193565A1 (en) * 1998-03-27 2002-12-19 Stanley Margaret Anne Antigen preparation and use
CN101245099A (zh) * 2007-02-14 2008-08-20 马润林 重组人乳头瘤病毒l1衣壳蛋白的氨基酸序列及其应用
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524076A (ja) 2002-04-30 2005-08-11 メルク　エンド　カムパニー　インコーポレーテッド ヒトパピローマウイルス多重アッセイ
US20130244228A1 (en) 2010-12-03 2013-09-19 Ralf Hilfrich Rapid test for the qualitative and/or quantitative analysis of antibodies against human papilloma viruses (hpv) present in body fluid, and device for carrying out the rapid test
US20140356861A1 (en) 2011-09-19 2014-12-04 Ralf Hilfrich Method for checking the self-healing process carried out by the immune system of a test subject infected with human papilloma virus

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
D. SKIBA，Prognostic Significance of Serum Antibodies to HPV-16 L1 Virus-like Particles in Patients with Invasive Cervical Cancer，ANTICANCER RESEARCH，2006年，Vol.26，Page.4921-4926
Eva Koslabova，Markers of HPV infection and survival in patients with head and neck tumors，International Journal of Cancer，2013年，Vol.133，Page.1832-1839
GRIT MEHLHORN，HPV16-L1-specific Antibody Response Is Associated with Clinical Remission of High-risk HPV-positive Early Dysplastic Lesions，ANTICANCER RESEARCH，2014年，Vol.34，Page.5127-5132
Hiroyuki Ochi，Do Neutralizing Antibody Responses Generated by Human Papillomavirus Infections Favor a Better Outcome of Low-Grade Cervical Lesions?，Journal of Medical Virology，2012年，Vol.84，Page.1128-1134
Jean Lacau St Guily，Human papillomavirus genotype distribution in tonsil cancers，Head & Neck Oncology，2011年，Vol.3 No.1，Page.6
Kurt Heim，Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer，Am J Obstet Gynecol，2002年，Vol.186，Page.705-711
Markus Schmitt，Diagnosing Cervical Cancer and High-Grade Precursors by HPV16 Transcription Patterns，Cancer Res;，2010年，Vol.70 No.1，Page.249-256
Marloes L. H. De Bruijn，L1-Specific Protection from Tumor Challenge Elicited by HPV16 Virus-like Particles，VIROLOGY，1998年，Vol.250，Page.371-376
NEIL D. CHRISTENSEN，Surface Conformational and Linear Epitopes on HPV-16 and HPV-18 L1 Virus-like Particles as Defined by Monoclonal Antibodies，VIROLOGY，1996年，Vol.223，Page.174-184
Qinjian Zhao，Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity，Virology Journal，2012年，Vol.9 No.1，Page.52
Stefania Bellone，Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines，JOURNAL OF VIROLOGY，2009年，Vol.83 No.13，Page.6779-6789
Tanja D. de Gruijl，Immunoglobulin G Responses Against Human Papillomavirus Type 16 Virus-Like Particles in a Prospective Nonintervention Cohort Study of Women With Cervical Intraepithelial Neoplasia，Journal of the National Cancer Institute，1997年，Vol.89 No.9，Page.630-638
Thomas Weilanda，DRH1 - a novel blood-based HPV tumour marker，EBioMedicine，2020年，Vol.56，Page.102804
Zhaohui Wang，A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera，Journal of General Virology，1997年，Vol.78，Page.2209-2215

Also Published As

Publication number Publication date
SI3384292T1 (sl) 2021-08-31
RU2757629C2 (ru) 2021-10-19
EP3384292B1 (en) 2021-04-21
KR102433541B1 (ko) 2022-08-18
LT3384292T (lt) 2021-07-26
KR20190097155A (ko) 2019-08-20
BR112019011681A2 (pt) 2019-10-15
ZA201804516B (en) 2019-04-24
RS62135B1 (sr) 2021-08-31
CY1124297T1 (el) 2022-07-22
RU2019121882A3 (https=) 2021-04-09
RU2019121882A (ru) 2021-01-15
SMT202100421T1 (it) 2021-09-14
JP2020501162A (ja) 2020-01-16
US20190113516A1 (en) 2019-04-18
US11506667B2 (en) 2022-11-22
ES2880489T3 (es) 2021-11-24
CN110073219B (zh) 2023-09-05
CN110073219A (zh) 2019-07-30
US20200408768A1 (en) 2020-12-31
EP3384292A1 (en) 2018-10-10
JP2023029377A (ja) 2023-03-03
PL3384292T3 (pl) 2021-10-25
DK3384292T3 (da) 2021-06-28
WO2018108957A1 (en) 2018-06-21
HRP20211080T1 (hr) 2021-10-01
HUE054969T2 (hu) 2021-10-28
CA3045729A1 (en) 2018-06-21
US10852303B2 (en) 2020-12-01
DE102016124171A1 (de) 2018-06-14
PT3384292T (pt) 2021-07-22

Similar Documents

Publication Publication Date Title
US7135281B2 (en) Screening for papilloma viruses
US20100167269A1 (en) Detection method for human pappilomavirus (HPV) and its application in cervical Cancer
US20150153345A1 (en) Antibodies specific to e6 proteins of hpv and use thereof
CN101538319A (zh) 用于多型人乳头瘤病毒检测的多肽及其用途
Lundstig et al. Serological diagnosis of human polyomavirus infection
Cason et al. Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type‐16 (HPV‐16) in sera from patients with cervical intraepithelial neoplasia and children
Xiao et al. Observations on the expression of human papillomavirus major capsid protein in HeLa cells
CN108276491B (zh) 一种可特异性识别hpv18 l1蛋白的单克隆抗体及其应用
JP2023029377A (ja) Ｈｐｖ１６陽性癌の治療コントロールのための血清検査
Ryding et al. Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles
Le Cann et al. Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16 L1 capsids produced by recombinant baculovirus
Baay et al. Humoral immune response against proteins E6 and E7 in cervical carcinoma patients positive for human papilloma virus type 16 during treatment and follow-up
DK3213078T3 (en) IMMUNOLOGICAL TEST TO DETECT E7 ONCOPROTEINES IN BIOLOGICAL SAMPLES
Egg et al. The Controversial Link Between Human Papillomavirus Infection and Esophageal Health: An Exploratory Translational Study
CN113444168A (zh) 一种抗hpv 35抗体及其制备方法和用途
JP4945730B2 (ja) 粘膜指向性ヒトパピローマウイルス群の感染予防ワクチン抗原
KR20220155712A (ko) 인유두종 바이러스 및 자궁경부암 감지용 다클론성 항체 및 이의 제조방법
CN113512109A (zh) 一种抗人乳头瘤病毒31型的单克隆中和抗体及其应用
Suzich et al. Characterization of a Major Neutralizing
CN111662378A (zh) Hpv18l1的单克隆中和抗体及其应用
Christensen et al. Identification of Two Cross-Neutralizing

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201214

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221215

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221215

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221226

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230410

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230731

R150 Certificate of patent or registration of utility model

Ref document number: 7329244

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150